GTF2B Full Name
general transcription factor IIB
GTF2B Introduction
For many researchers and drug developers working at the interface of transcriptional regulation and disease biology, identifying upstream regulators that truly control gene expression dynamics remains a persistent challenge. GTF2B, which encodes the general transcription factor IIB (TFIIB), has emerged as a pivotal node in this landscape. As a core component of the RNA polymerase II (Pol II) preinitiation complex (PIC), TFIIB functions as a molecular bridge linking TATA-binding protein (TBP) within TFIID to Pol II, thereby orchestrating the precise assembly of the transcriptional machinery. Beyond its classical role in transcription initiation, accumulating evidence highlights that TFIIB participates in multiple stages of the transcription cycle, including promoter recognition, start site selection, stabilization of the PIC, and the transition from initiation to elongation. Its conserved structural features, particularly the B-finger domain that directly interacts with the Pol II active center, enable TFIIB to fine-tune transcriptional efficiency and fidelity, making it a critical determinant of gene expression output in both normal and pathological contexts.
A growing body of cancer research has brought GTF2B into focus as a potential oncogenic driver, especially in solid tumors such as hepatocellular carcinoma (HCC). One of the key pain points in oncology is the lack of robust biomarkers that not only correlate with tumor progression but also provide mechanistic insight into proliferation control. Recent studies have demonstrated that GTF2B is significantly overexpressed in HCC tissues compared to normal liver, with expression levels positively correlating with poor histological differentiation, elevated alpha-fetoprotein (AFP), and proliferation markers such as Ki-67. Mechanistically, GTF2B exhibits cell cycle–dependent regulation, with pronounced upregulation during the G1/S transition, where it promotes DNA synthesis and cell proliferation, partly through the induction of proliferating cell nuclear antigen (PCNA). These findings position GTF2B not merely as a passive transcription factor, but as an active regulator of oncogenic transcriptional programs. As such, it holds promise as both a diagnostic biomarker and a therapeutic target, particularly for strategies aimed at disrupting transcriptional addiction in cancer cells.
In addition to its role in cancer, GTF2B has gained increasing attention in the context of viral infection and immune-mediated diseases, addressing another major challenge in biomedical research: understanding how host transcriptional machinery is hijacked or dysregulated. Viruses, including both DNA and RNA types, rely heavily on host TFIIB to initiate transcription of their own genomes, often targeting and stabilizing this factor to enhance viral gene expression while suppressing host antiviral responses. Intriguingly, host cells counteract this process by inducing TFIIB degradation through ubiquitin-mediated pathways or caspase-3 cleavage under stress conditions such as DNA damage or infection. However, certain viruses can block this degradation, ensuring sustained transcriptional support for replication. Beyond infectious disease, integrative bioinformatics analyses have identified GTF2B as a potential biomarker in autoimmune conditions such as lupus nephritis, where its dysregulated expression is associated with altered immune cell infiltration and activation of key signaling pathways, including T cell receptor, B cell receptor, and Toll-like receptor pathways. Together, these insights underscore GTF2B as a multifunctional regulatory hub whose subtle expression changes can profoundly influence cell fate decisions, immune responses, and disease progression, making it an increasingly attractive target for both mechanistic studies and therapeutic intervention.
Alternate Names for GTF2B
GTF2B
general transcription factor IIB
TF2B
TFIIB
transcription initiation factor IIB
S300-II
general transcription factor TFIIB
RNA polymerase II transcription factor IIB
